Default company panoramic image

Sophia Genetics SA

Sophia Genetics is a Swiss company aiming to optimize drug treatments by making best use of genetic tests. Customers are diagnostic laboratories and phramace...

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Chemin du Croset, Ecublens, VD, Switzerland
  • Currency CHF
  • Founded March 2011
  • Employees 3
  • Website

Company Summary

Sophia Genetics is a Swiss company aiming to optimize drug treatments by making best use of genetic tests. Customers are diagnostic laboratories and phramaceutical companies. We support their activities with a web based itegrated platform for patient DNA seuqnce banking, qulity check and analysis.


  • Default avatar
    Jurgi Camblong
    Co-founder and CEO

    Dr. Camblong is a young entrepreneur whose training was in biochemistry and molecular biology.

    He obtained his PhD in the field of gene regulation at the University of Geneva in 2007 before continuing in this area at Oxford University as a postdoctoral fellow.

    In 2010, Dr. Camblong entered the start-up scene, becoming the CEO of Gene Predictis.

    During his time there, he led the company’s developments to redefine the business.

    Since Se

  • Default avatar
    Pierre Hutter
    Co-founder and CSO

    Dr. Hutter is one of the most renowned medical geneticists in Switzerland.

    He completed his PhD in genetics in Edinburgh and his postdoctoral work in Cambridge (UK).

    He discovered the landmark speciation gene Hmr (Hybrid male rescue) in Drosophila, which has become the most studied gene in the field of reproductive isolation.

    Since 2005, he has been co-director of the Geneva University laboratory of Predictive Oncology, one of the two re

  • Default avatar
    Lars Steinmetz

    Dr. Steinmetz is an established scientist at the forefront of genetics and genomics research.

    He obtained his undergraduate degree from Yale University and a PhD in 2002 from Stanford University.

    At the young age of 27, he started his own research group at the European Molecular Biology Laboratory (EMBL), whose aim is to dissect the molecular events that lead from genotype to phenotype.

    In 2009, Dr. Steinmetz was promoted to co-chair of

  • Default avatar
    Denis Hochstrasser
    Board member

    Prof. Denis Hochstrasser is an authority on clinical and laboratory medicine, with expertise across proteomics, chemistry, computer sciences, and internal medicine.

    He is the chairman of the Genetic & Laboratory Medicine Department of the Geneva University Hospital and former Vice Dean of the Faculty of Medicine.

    At the academic level, he is a full professor, both to Geneva's Department of Structure Biology & Bioinformatics, Medicine Facult

  • Default avatar
    Edouard Croufer
    Board member

    Edouard Croufer is an acclaimed expert in the management and development of strategies in pharmaceutical and chemical industries.

    He was General Director of the Chemical and Pharma Sectors at UCB from 1993 to 2004, during which he was also a member of the Executive Committee of the UCB Group and Vice President of the Belgian federation of Chemical Industry.

    Since 2004, he has been a Global Director of the management consultancy Arthur D. Li


  • Default avatar
    Me Jacques Bonvin (Tavernier Tschanz )
    Default avatar
    Véronique Penseyres (Flexadmin)

Previous Investors

  • Default avatar
    Private investors
    Default avatar
    A3 Angels